Additionally, in those patients with TSC1 mutated bladder cancer, inhibition of HDACs can potentially restore Hsp90 acetylation and sensitivity to Hsp90 inhibitors. The gene discussed is HSP90AA1; the disease is urinary bladder carcinoma.